Soochow Securities·2025-10-19 11:55Investment Rating - The report maintains a rating of "Buy" for the pharmaceutical and biotechnology sector, specifically recommending companies like Zhaoli Pharmaceutical and Fangsheng Pharmaceutical as undervalued high-dividend Chinese medicine stocks [1]. Core Insights - The report highlights that the Chinese medicine sector is characterized by strong cash flow and low debt ratios, making it capable of high dividend payouts. This sector is less affected by international political dynamics, making it a viable defensive strategy in a volatile market [16][17]. - The report ranks sub-sectors in the following order of preference: innovative drugs > research services > CXO > Chinese medicine > medical devices > pharmacies [10][12]. Summary by Sections 1. Significant Excess Returns in Pharmaceutical Stocks - The A-share pharmaceutical index has shown a year-to-date increase of 18.85%, with a weekly decline of 2.48%. The Chinese medicine sector saw a slight increase of 0.38%, while other sectors like medical services and medical devices experienced declines [4][9]. 2. High Dividend Yield in Chinese Medicine Sector - The report emphasizes the attractiveness of high dividend yields in the Chinese medicine sector, with companies like Zhaoli Pharmaceutical expected to have a dividend yield of 4.1% in 2025, and Fangsheng Pharmaceutical at 3.1% [17][18]. 3. R&D Progress and Company Dynamics - Recent developments include the approval of innovative drugs and clinical trials by various companies, indicating ongoing advancements in the sector [4][12]. 4. Industry and Regulatory Insights - The report provides insights into the regulatory landscape affecting the pharmaceutical industry, noting that the impact of tariff wars on the sector is limited [4]. 5. Market Review - The report tracks the performance of various pharmaceutical sub-sectors, noting that the Chinese medicine sector has outperformed others in recent weeks [4][9].